Previous close | 0.1300 |
Open | 0.0300 |
Bid | 0.0000 |
Ask | 0.0600 |
Strike | 60.00 |
Expiry date | 2024-05-17 |
Day's range | 0.0300 - 0.0300 |
Contract range | N/A |
Volume | |
Open interest | 1.18k |
Merck (MRK), Sanofi (SNY), Novartis (NVS) and AstraZeneca (AZN) announce their first-quarter results.
Fusion (FUSN) is expected to provide updates regarding the developmental program of its lead candidate, FPI-2265, for prostate cancer in the first-quarter earnings release.
AstraZeneca stock bolted higher Thursday — and is now within striking distance of a breakout — after its cancer drugs propelled a sales beat.